New Market Study Published: Latvia Pharmaceuticals & Healthcare Report Q1 2013
BMI View: Our view of the Latvian pharmaceutical market remains shaped by the prevailing economic conditions given the high out-of-pocket contributions to medicine spending. This is especially pertinent as the government has over the recent months cut healthcare spending in a bid to remain eligible for EU and IMF loan packages, as well in preparation for potential eurozone membership. While we still expect the market to contract in US dollar terms in 2012, the contraction is expected to be less...
View full press release